These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 37452933)

  • 21. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
    Hargrave D
    Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy and Response Assessment in Malignant Glioma: Neuro-oncology Perspective.
    Bagley SJ; Desai AS; Nasrallah MP; O'Rourke DM
    Top Magn Reson Imaging; 2020 Apr; 29(2):95-102. PubMed ID: 32271286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell immunotherapy for malignant gliomas.
    Luptrawan A; Liu G; Yu JS
    Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapies for malignant gliomas: a local affair?
    Rainov NG; Söling A; Heidecke V
    Neurosurg Focus; 2006 Apr; 20(4):E9. PubMed ID: 16709040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Gliomas in adults: primary non-surgical treatment].
    Poulsen HS
    Ugeskr Laeger; 2006 Nov; 168(47):4082-5. PubMed ID: 17134603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.
    Chelliah SS; Paul EAL; Kamarudin MNA; Parhar I
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33671796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular pathology and clinical implications of diffuse glioma.
    Chai R; Fang S; Pang B; Liu Y; Wang Y; Zhang W; Jiang T
    Chin Med J (Engl); 2022 Dec; 135(24):2914-2925. PubMed ID: 36728558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell-based immunotherapy for malignant gliomas.
    Akasaki Y; Black KL; Yu JS
    Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.
    Delgado-López PD; Corrales-García EM; Martino J; Lastra-Aras E; Dueñas-Polo MT
    Clin Transl Oncol; 2017 Aug; 19(8):931-944. PubMed ID: 28255650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caring for Patients with Newly Diagnosed High-Grade Gliomas.
    Grossman SA; Piotrowski AF
    Semin Neurol; 2016 Aug; 36(4):324-9. PubMed ID: 27643899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).
    Sepúlveda-Sánchez JM; Muñoz Langa J; Arráez MÁ; Fuster J; Hernández Laín A; Reynés G; Rodríguez González V; Vicente E; Vidal Denis M; Gallego Ó
    Clin Transl Oncol; 2018 Jan; 20(1):3-15. PubMed ID: 29124520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Principles of treatment of malignant gliomas in adults: an overview.
    Azizi SA; Miyamoto C
    J Neurovirol; 1998 Apr; 4(2):204-16. PubMed ID: 9584957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adults with newly diagnosed high-grade gliomas.
    Croteau D; Mikkelsen T
    Curr Treat Options Oncol; 2001 Dec; 2(6):507-15. PubMed ID: 12057096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biology and treatment of malignant glioma.
    Prados MD; Levin V
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):1-10. PubMed ID: 10866344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy and immunotherapy in adult malignant gliomas.
    Chatel M; Lebrun C; Frenay M
    Curr Opin Oncol; 1993 May; 5(3):464-73. PubMed ID: 8494907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets.
    Fuller GN; Hess KR; Rhee CH; Yung WK; Sawaya RA; Bruner JM; Zhang W
    Brain Pathol; 2002 Jan; 12(1):108-16. PubMed ID: 11771519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.